Carisma Therapeutics Inc. Annual Weighted Average Number of Shares Outstanding, Diluted from 2014 to 2023

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Carisma Therapeutics Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from 2014 to 2023.
  • Carisma Therapeutics Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2024 was 41.6M shares, a 3.23% increase year-over-year.
  • Carisma Therapeutics Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 33.5M shares, a 1475% increase from 2022.
  • Carisma Therapeutics Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 2.13M shares, a 98.8% decline from 2021.
  • Carisma Therapeutics Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 182M shares, a 54.2% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 33.5M +31.4M +1475% Jan 1, 2023 Dec 31, 2023 10-K 2024-04-01
2022 2.13M -180M -98.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-04-01
2021 182M +64.1M +54.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-28
2020 118M +27.3M +30% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 90.9M +29.2M +47.2% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 61.8M +35.7M +137% Jan 1, 2018 Dec 31, 2018 10-K 2019-03-01
2017 26.1M +4.37M +20.1% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-01
2016 21.7M +2.74M +14.4% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-01
2015 19M +4.35M +29.7% Jan 1, 2015 Dec 31, 2015 10-K 2018-04-02
2014 14.6M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.